Therapeutic Small Bowel Endoscopy

Author(s):  
Peter B.F. Mensink ◽  
Huseyin Aktas
Endoscopy ◽  
2007 ◽  
Vol 39 (02) ◽  
pp. 113-117 ◽  
Author(s):  
G. Eisen ◽  
M. Schreiner

2015 ◽  
Vol 6 (2) ◽  
pp. 132-140 ◽  
Author(s):  
Melissa F Hale ◽  
Carolyn Davison ◽  
Simon Panter ◽  
Kaye Drew ◽  
David S Sanders ◽  
...  

2013 ◽  
pp. 515-536
Author(s):  
Richard Ho ◽  
Richard M. Mendelson

2019 ◽  
Vol 55 (5) ◽  
pp. 481-495 ◽  
Author(s):  
Toshio Watanabe ◽  
Yasuhiro Fujiwara ◽  
Francis K. L. Chan

AbstractRecent advances in small-bowel endoscopy such as capsule endoscopy have shown that non-steroidal anti-inflammatory drugs (NSAIDs) frequently damage the small intestine, with the prevalence rate of mucosal breaks of around 50% in chronic users. A significant proportion of patients with NSAIDs-induced enteropathy are asymptomatic, but some patients develop symptomatic or complicated ulcers that need therapeutic intervention. Both inhibition of prostaglandins due to the inhibition of cyclooxygenases and mitochondrial dysfunction secondary to the topical effect of NSAIDs play a crucial role in the early process of injury. As a result, the intestinal barrier function is impaired, which allows enterobacteria to invade the mucosa. Gram-negative bacteria and endogenous molecules coordinate to trigger inflammatory cascades via Toll-like receptor 4 to induce excessive expression of cytokines such as tumor necrosis factor-α and to activate NLRP3 inflammasome, a multiprotein complex that processes pro-interleukin-1β into its mature form. Finally, neutrophils accumulate in the mucosa, resulting in intestinal ulceration. Currently, misoprostol is the only drug that has a proven beneficial effect on bleeding small intestinal ulcers induced by NSAIDs or low-dose aspirin, but its protection is insufficient. Therefore, the efficacy of the combination of misoprostol with other drugs, especially those targeting the innate immune system, should be assessed in the next step.


Endoscopy ◽  
2019 ◽  
Vol 51 (06) ◽  
pp. 574-598 ◽  
Author(s):  
Cristiano Spada ◽  
Deirdre McNamara ◽  
Edward J. Despott ◽  
Samuel Adler ◽  
Brooks D. Cash ◽  
...  

AbstractThe European Society of Gastrointestinal Endoscopy (ESGE) together with the United European Gastroenterology (UEG) recently developed a short list of performance measures for small-bowel endoscopy (i. e. small-bowel capsule endoscopy and device-assisted enteroscopy) with the final goal of providing endoscopy services across Europe with a tool for quality improvement. Six key performance measures for both small-bowel capsule endoscopy and for device-assisted enteroscopy were selected for inclusion, with the intention being that practice at both a service and endoscopist level should be evaluated against them. Other performance measures were considered to be less relevant, based on an assessment of their overall importance, scientific acceptability, and feasibility. Unlike lower and upper gastrointestinal endoscopy, where performance measures had already been identified, this is the first time that small-bowel endoscopy quality measures have been proposed.


2018 ◽  
Vol 57 (11) ◽  
pp. 1577-1581 ◽  
Author(s):  
Kohei Okayama ◽  
Yoshikazu Hirata ◽  
Daisuke Kumai ◽  
Yuki Yamamoto ◽  
Yuki Kojima ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document